Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004060 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancer
A Phase 2 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00004060: Completed Phase 2 study, sponsored by Daiichi Sankyo.
NCT00004060 is a Phase 2 study that has completed, run by Daiichi Sankyo. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004060, a Phase 2 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DX-8951f in treating patients who have recurrent, metastatic, or unresectable ovarian, fallopian tube, or peritoneal cancer.
Interventions
- DRUG exatecan mesylate
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-07 |
| Est. Completion | 2000-09 |
| Phase | Phase 2 |
What the finished NCT00004060 record still lists
NCT00004060 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which exatecan mesylate is the first listed.
NCT00004060 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00004060 about?
NCT00004060 is a clinical study titled "Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DX-8951f in treating patients who have recurrent, metastatic, or unresectable ovarian, fallopian tube, or peritoneal cancer.
What is the current status of trial NCT00004060?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-07. Estimated completion is 2000-09.
What interventions are being tested in trial NCT00004060?
The interventions under investigation include: exatecan mesylate (DRUG).
Who is sponsoring clinical trial NCT00004060?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia